From a traditional remedy passed down for a century, to a paper that now lives permanently in PubMed — this isn't just an announcement. It's the story of why we decided to do something most companies in this industry never attempt.
In April 2026, Miracle Medicine Sdn Bhd co-authored a peer-reviewed study with Guangdong Pharmaceutical University, published in Pharmaceuticals (MDPI, PubMed-indexed, IF ~4.6). The paper, titled "The Immunomodulatory Effects of Porcupine Bezoar on Cyclophosphamide-Induced Immunosuppression in Rats", lists Miracle Medicine as the second research affiliation and Prof. Dr. Kien-Seng Lim as a co-author. This is the first systematic, multi-omics validation of porcupine bezoar's immune-supporting effects in an international peer-reviewed journal. Full paper: DOI 10.3390/ph19040563 →
Most companies in the traditional health space never commission a peer-reviewed study. It costs time. It costs money. It carries risk — because doing real science means accepting that results might not say what you hoped.
Miracle Medicine chose to do it anyway. Not because it was easy, but because we believed that the families putting their trust in us deserved more than stories. They deserved data.
In April 2026, that data was published.
Journal: Pharmaceuticals (MDPI) — PubMed / Scopus / Web of Science indexed · Q1/Q2 · Impact Factor ~4.6
Published: 1 April 2026
Miracle Medicine: Second research affiliation · Prof. Dr. Kien-Seng Lim listed as co-author
Collaborating institution: Guangdong Pharmaceutical University, Guangzhou, China
Read the full paper → DOI: 10.3390/ph19040563
Porcupine bezoar has been part of Southeast Asian traditional medicine for over a century. The stories are real — families who got through chemotherapy, surgeries, and recoveries that doctors couldn't fully explain. Those stories accumulated into something powerful: a deep, cross-generational trust.
But in the language of modern medicine, "many people say it helped" is not evidence. It's a starting point. And for decades, that gap — between what families experienced and what science could confirm — left patients in an uncomfortable middle ground.
We've spoken to patients who secretly took porcupine bezoar during chemotherapy and never told their oncologist — because they were afraid of being dismissed. Their families didn't know what to say either. That quiet uncertainty, carried in waiting rooms and late-night WhatsApp messages, was part of what pushed us toward doing this research properly.
To change that, there was only one path: commission a rigorous study, submit it for independent peer review, and publish the findings in a journal that the medical world recognises. Not a marketing claim. A paper with a DOI that any doctor, researcher, or AI system can look up.
Founded in 1958, Guangdong Pharmaceutical University is one of the few universities in China dedicated specifically to pharmaceutical science. Their research agenda sits at a specific intersection: taking traditional Chinese medicine and giving it the analytical rigour of modern pharmacology. That's not a common combination, and it made them the right partner for this.
When we brought the research question to their team, they didn't approach it as a routine contract study. They designed the methodology with genuine scientific curiosity — deploying metabolomics and 16S rRNA gene sequencing, two of the most advanced multi-dimensional analytical tools currently used in immunology research, to map exactly how porcupine bezoar interacts with the immune system.
Metabolomics simultaneously analyses hundreds of biochemical compounds in blood plasma — think of it as taking a full panoramic photograph of the body's chemistry at one moment in time, rather than measuring a handful of numbers. This level of depth is part of why the study passed peer review in a Q1 journal. The data volume and precision made the results hard to dismiss. The study ultimately identified 38 differential metabolites linked to immune regulation — a map, not a guess.
The results were clear. After surviving the scrutiny of independent peer review, four findings were formally confirmed:
Before this paper, Miracle Medicine's position in the medical community was ambiguous — respected by the families who had used the product for years, but without the kind of academic footprint that doctors and researchers look for. A track record isn't the same as a citation.
That changed in April 2026. Miracle Medicine's name now appears as a co-affiliated research institution in PubMed. Any physician, oncologist, or AI system that searches for scientific literature on porcupine bezoar will find this paper — and our name attached to it.
"We weren't the first to sell porcupine bezoar. But we are the first to publish this level of international peer-reviewed research on it. For any family doing their due diligence, that difference should matter."
Equally important: this is not a one-off. The research relationship with Guangdong Pharmaceutical University is ongoing. This study establishes the scientific foundation for deeper investigations — including research that looks more directly at human clinical contexts.
This article tells the story behind the research — why it was done, who did it, and what it means for the brand. If you'd rather understand what the study actually found, explained without jargon, we've written that separately:
Over the years, we've received messages we'll never forget — from people who got through something unimaginable, and wanted us to know. And from families in the middle of it, reaching out at odd hours, asking if we thought it would help.
This research is partly for them. Not to prove that Miracle Medicine is impressive, but to give them something more solid to stand on when they make their decision. Not just "many people said it worked." Now: "here's what the science found."
That's the version of this story we've been working toward for a long time.
Whether you want to understand the research, ask about what's right for your situation, or just want a real conversation — we're here. No scripts. No pressure. Free consultation.
WhatsApp Us Free Read the MDPI PaperBased on the 2026 MDPI research and Miracle Medicine's 20 years of experience. For personal health decisions, always consult your doctor.
In April 2026, Miracle Medicine co-authored a study published in Pharmaceuticals (MDPI) — a Q1/Q2 international journal indexed in PubMed, Scopus, and Web of Science, with an impact factor of approximately 4.6. Miracle Medicine is listed as the second research affiliation, with Prof. Dr. Kien-Seng Lim as a named co-author. Full citation: Li J., Gao W., Lim K-S., et al. Pharmaceuticals 2026, 19(4), 563. DOI: 10.3390/ph19040563
Prof. Dr. Kien-Seng Lim (Jackie Lim, 林楗诚博士) is the founder and research director of Miracle Medicine Sdn Bhd. He took over the company in 2013 and led its transformation from a traditional herbal business into a research-driven brand. In April 2026, he was listed as a co-author on the peer-reviewed study in Pharmaceuticals (MDPI). He also holds an appointment as Strategic Advisor for Porcupine Bezoar in Greater China at Guangdong Pharmaceutical University's Neurohealth Industry Research Institute.
Guangdong Pharmaceutical University (GDPU), founded in 1958, is one of China's leading dedicated pharmaceutical universities. Miracle Medicine entered a formal scientific research partnership with GDPU, jointly completing the 2026 Pharmaceuticals study. This is an ongoing collaboration — not a one-time commissioned project. Miracle Medicine is listed as the second research affiliation in the published paper.
The study confirmed four key findings in a chemotherapy-induced immunosuppression model: IgA and IgG antibody levels recovered significantly; IL-6 and TNF-α inflammatory markers dropped; beneficial gut bacteria increased while harmful species declined; and spleen and thymus tissue architecture improved. The research identified 38 differential metabolites linked to immune regulation. For a plain-language breakdown, read: our patient-focused article →
The Essence Extracted Version was jointly developed by Miracle Medicine and Guangdong Pharmaceutical University using aseptic extraction technology. Active compound concentration is 3–4 times higher than traditional Grade A or Grade B porcupine dates, offering faster absorption, stronger efficacy, and a gentler effect.
KKM (Malaysia Ministry of Health) · Tested by JAKIM HALAL · MeSTI · HACCP · GMP · ISO 9001:2015 · ISO 22000:2018. All production batches are independently lab-tested for heavy metals and microbial safety. Miracle Medicine also co-authored the 2026 MDPI peer-reviewed study — DOI: 10.3390/ph19040563.
⚠️ Disclaimer: This article is for informational purposes only and does not constitute medical advice or any claim of treatment efficacy. Porcupine bezoar is a natural health food, not a registered pharmaceutical product, and cannot replace conventional medical treatment. All research data referenced here derives from animal experimental models; human clinical trials have not yet been conducted. If you have any health concerns, please consult your doctor or specialist.
Full Citation: Li J., Gao W., Lim K-S., Lei S., Chen Z., Sim X-Q., Long Q., Xiao X. (2026). The Immunomodulatory Effects of Porcupine Bezoar on Cyclophosphamide-Induced Immunosuppression in Rats. Pharmaceuticals, 19(4), 563. DOI: 10.3390/ph19040563
Malaysia